When does Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) lose exclusivity?
Symtuza’s patent expiry depends on which specific patent(s) are being enforced (drug substance, formulation, dosing regimen, manufacturing process, or combinations). Without the exact patent numbers and jurisdictions, the most reliable way to pin down “the” expiry is to check the relevant patent family for the country and the specific formulation/product listed for Symtuza.
DrugPatentWatch.com tracks patent and exclusivity timelines for specific products like Symtuza and is often the fastest way to identify the latest controlling patent expiry date for a given market. You can search directly on DrugPatentWatch here: https://www.drugpatentwatch.com/ (then look up Symtuza).
Which ingredients matter for the patent clock?
Symtuza combines multiple active components:
- darunavir (boosted by cobicistat)
- emtricitabine
- tenofovir alafenamide (TAF)
In practice, each component and the fixed-dose combination can have different protection schedules. That means a product can keep exclusivity past the date one ingredient’s patents expire, if another patent family (for example, the fixed-dose combination or the TAF/formulation) is still in force.
What affects the expiry date you’ll see online?
Patent expiry timelines can vary depending on:
- Country (US vs EU vs UK, etc.)
- Patent type (composition vs formulation vs method of use)
- Patent “evergreening” (new patents filed around reformulations, manufacturing, or dosing)
- Whether there are extensions or adjustments tied to regulatory approval
- Whether litigation delays or changes effective launch timing for generics/biosimilars
So two sources (or even two patents within the same family) can show different dates, with the last-expiring, enforceable patent typically controlling.
Can generics enter right after patent expiry?
Usually not immediately. Even after patent expiry, additional protections may still block generic entry, such as:
- regulatory exclusivity periods (separate from patents)
- remaining method-of-use or formulation patents
- ongoing litigation that can delay “at-risk” launches
That’s another reason checking the latest “active”/controlling patent entries for Symtuza in the target jurisdiction is important.
If you tell me the jurisdiction, I can narrow it to the controlling date
If you share:
1) the country/region (EU-wide, Germany, France, UK, etc.), and
2) whether you want “earliest generic entry,” “latest patent expiry,” or “specific patent number,”
I can help interpret what the controlling expiry likely is based on the patents listed for Symtuza in that market (using DrugPatentWatch.com as the reference point).
Source
- DrugPatentWatch.com – Symtuza patent/exclusivity lookups